Improving Primary Care Management of IBS-D through Early Diagnosis and Personalized Treatment

Release date: September 15, 2018
Expiration date: September 15, 2019

 

FACULTY

Lucinda Harris, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Gastroenterology & Hepatology
Mayo Clinic College of Medicine
Scottsdale, Arizona

PROGRAM OVERVIEW

This case-based enduring activity will cover the diagnosis, treatment and management of patients with IBS-D.

TARGET AUDIENCE

This educational initiative has been designed for primary care providers (PCPs), nurse practitioners, and physician assistants involved in the care of patients with IBS-D.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be better able to:

  • Apply an approach to the diagnosis of IBS-D that is consistent with current evidence-based guidelines
  • Identify strategies for encouraging effective provider-patient communication to improve assessment of disease burden in patients with IBS-D
  • Summarize current evidence regarding efficacy and safety of available options for the treatment of IBS-D
DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 15, 2018 through September 15, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Lucinda Harris, MD, MS
Consultant: Allergan, Napo Pharmaceuticals, Shire, Synergy
Speakers’ Bureaus: Allergan, Ironwood

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10

Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

This CME activity is provided by Integrity Continuing Education.

SUPPORTER ACKNOWLEDGMENT

This activity is supported by an independent education grant from Salix Pharmaceuticals, Inc., a division of Valeant Pharmaceuticals North America LLC.

Continue to Pretest